Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more
Beijing Konruns Pharmaceutical Co Ltd (603590) - Net Assets
Latest net assets as of September 2025: CN¥3.49 Billion CNY
Based on the latest financial reports, Beijing Konruns Pharmaceutical Co Ltd (603590) has net assets worth CN¥3.49 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.05 Billion) and total liabilities (CN¥563.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.49 Billion |
| % of Total Assets | 86.08% |
| Annual Growth Rate | 24.28% |
| 5-Year Change | 11.1% |
| 10-Year Change | 401.44% |
| Growth Volatility | 26.58 |
Beijing Konruns Pharmaceutical Co Ltd - Net Assets Trend (2013–2024)
This chart illustrates how Beijing Konruns Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Konruns Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual net assets of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.43 Billion | +1.90% |
| 2023-12-31 | CN¥3.36 Billion | +5.40% |
| 2022-12-31 | CN¥3.19 Billion | +1.90% |
| 2021-12-31 | CN¥3.13 Billion | +1.51% |
| 2020-12-31 | CN¥3.08 Billion | +13.05% |
| 2019-12-31 | CN¥2.73 Billion | +9.97% |
| 2018-12-31 | CN¥2.48 Billion | +83.04% |
| 2017-12-31 | CN¥1.36 Billion | +54.91% |
| 2016-12-31 | CN¥874.92 Million | +28.05% |
| 2015-12-31 | CN¥683.27 Million | +40.01% |
| 2014-12-31 | CN¥488.02 Million | +55.69% |
| 2013-12-31 | CN¥313.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Konruns Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3455.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.96 Billion | 62.48% |
| Common Stock | CN¥159.36 Million | 5.07% |
| Other Comprehensive Income | CN¥144.75 Million | 4.60% |
| Other Components | CN¥875.72 Million | 27.85% |
| Total Equity | CN¥3.14 Billion | 100.00% |
Beijing Konruns Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Beijing Konruns Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Verallia
PA:VRLA
|
$444.22 Million |
|
S.J.S. Enterprises Limited
NSE:SJS
|
$444.46 Million |
|
Finolex Industries Limited
NSE:FINPIPE
|
$444.49 Million |
|
Ningxia Building Materials Group Co Ltd
SHG:600449
|
$444.49 Million |
|
Tengda Construction Group Co Ltd
SHG:600512
|
$443.86 Million |
|
Adriatic Metals PLC
PINK:ADTLF
|
$443.66 Million |
|
Ricegrowers Ltd
AU:SGLLV
|
$443.61 Million |
|
Xingyuan Environment Technology Co Ltd
SHE:300266
|
$443.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Konruns Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,059,941,948 to 3,144,412,325, a change of 84,470,377 (2.8%).
- Net income of 42,216,735 contributed positively to equity growth.
- Dividend payments of 53,492,097 reduced retained earnings.
- Share repurchases of 2,598,492 reduced equity.
- Other comprehensive income increased equity by 65,745,566.
- Other factors increased equity by 32,598,665.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥42.22 Million | +1.34% |
| Dividends Paid | CN¥53.49 Million | -1.7% |
| Share Repurchases | CN¥2.60 Million | -0.08% |
| Other Comprehensive Income | CN¥65.75 Million | +2.09% |
| Other Changes | CN¥32.60 Million | +1.04% |
| Total Change | CN¥- | 2.76% |
Book Value vs Market Value Analysis
This analysis compares Beijing Konruns Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.60x to 1.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥2.61 | CN¥38.09 | x |
| 2014-12-31 | CN¥4.08 | CN¥38.09 | x |
| 2015-12-31 | CN¥5.70 | CN¥38.09 | x |
| 2016-12-31 | CN¥7.30 | CN¥38.09 | x |
| 2017-12-31 | CN¥11.29 | CN¥38.09 | x |
| 2018-12-31 | CN¥18.61 | CN¥38.09 | x |
| 2019-12-31 | CN¥17.05 | CN¥38.09 | x |
| 2020-12-31 | CN¥19.24 | CN¥38.09 | x |
| 2021-12-31 | CN¥18.35 | CN¥38.09 | x |
| 2022-12-31 | CN¥18.70 | CN¥38.09 | x |
| 2023-12-31 | CN¥19.52 | CN¥38.09 | x |
| 2024-12-31 | CN¥20.11 | CN¥38.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Konruns Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.11%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.25x
- Recent ROE (1.34%) is below the historical average (16.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 37.96% | 47.31% | 0.49x | 1.65x | CN¥87.24 Million |
| 2014 | 36.04% | 57.92% | 0.46x | 1.36x | CN¥127.09 Million |
| 2015 | 28.58% | 44.77% | 0.52x | 1.24x | CN¥126.92 Million |
| 2016 | 21.91% | 55.36% | 0.34x | 1.17x | CN¥104.16 Million |
| 2017 | 35.33% | 81.08% | 0.35x | 1.24x | CN¥343.29 Million |
| 2018 | 10.64% | 27.12% | 0.33x | 1.18x | CN¥15.86 Million |
| 2019 | 9.75% | 24.96% | 0.34x | 1.16x | CN¥-6.72 Million |
| 2020 | 5.96% | 22.67% | 0.21x | 1.23x | CN¥-124.48 Million |
| 2021 | 5.12% | 18.27% | 0.24x | 1.17x | CN¥-140.89 Million |
| 2022 | 3.47% | 11.71% | 0.25x | 1.17x | CN¥-191.10 Million |
| 2023 | 4.92% | 16.35% | 0.24x | 1.24x | CN¥-155.54 Million |
| 2024 | 1.34% | 5.11% | 0.21x | 1.25x | CN¥-272.22 Million |
Industry Comparison
This section compares Beijing Konruns Pharmaceutical Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Konruns Pharmaceutical Co Ltd (603590) | CN¥3.49 Billion | 37.96% | 0.16x | $444.00 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |